New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:39 EDTCPXXCelator Pharmaceuticals initiates PK/PD clinical study of CPX-351
Celator Pharmaceuticals announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics, or PK/PD, study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, and myelodysplastic syndrome, or MDS. This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
07:42 EDTCPXXBioCentury to hold a conference
Subscribe for More Information
March 17, 2015
16:12 EDTCPXXCelator Pharmaceuticals sees sufficient funding into second half of 2016
Subscribe for More Information
16:11 EDTCPXXCelator Pharmaceuticals reports Q4 EPS (7c), consensus (16c)
Cash and cash equivalents as of December 31, 2014 were $32.4M, compared to $23.6M as of December 31, 2013. The following are expected milestones for the company: CPX-351 Phase 3 study: 2Q15 Induction response rate; 1Q16 Overall survival data. Technology platform: 3Q15 information packages for novel combinations.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use